Literature DB >> 34994942

BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.

Mohamed A Abdelrazek1,2, Ahmed Nageb3, Lamiaa A Barakat3, Amr Abouzid4, Rizk Elbaz5.   

Abstract

BACKGROUND: Early accurate breast cancer (BC) diagnosis is critical in disease management. Mammography has been widely used. However, its radiation, and high false-negative and -positive results have always been a concern. We evaluated combined detection of human epididymal protein 4 (HE4) and trefoil factor 3 (TFF3) as substitute method to enhance BC diagnosis.
METHODS: HE4 and TFF3 blood levels were determined by ELISA in sera of 120 BC patients and 80 women (40 healthy and 40 benign breast disease) as controls. Receiver-operating characteristic curve was applied for evaluation diagnostic power of each biomarker and their combination.
RESULTS: In BC patients, serum HE4 [5 (2-11.9) vs. 3.1 (1.8-5.4) and 1 (1-3.5); P = 0.022] and TFF3 [5.3 (4.5-6.7) vs. 4.7 (4-4.8) and 3.9 (3-4.4); P = 0.027] were significantly higher than that in benign and healthy groups, respectively. Both HE4 (AUC = 0.783; P < 0.0001) and TFF3 (AUC = 0.759; P < 0.0001) had superior BC diagnostic ability compared to CEA and CA-15.3. Logistic regression analysis revealed simplified index BC-DETECT = HE4 + TFF3, and its values were significantly (P = 0.0132) elevated in BC (10.9 (8.4-17.2) compared to benign (7.2 (5.4-10.1)) and healthy (5.1 (4-6.3)) controls. AUC of BC-DETECT for BC prediction was (AUC = 0.850; P < 0.0001) with sensitivity, specificity, and positive and negative predictive values and accuracy of 84.2%, 70%, 80.8%, 74.7%, and 78.5%, respectively. High BC-DETECT levels were associated with tumor non-luminal subtypes, late stage, high grade, large size, lymph-node invasion, and multiple lesions.
CONCLUSIONS: BC-DETECT is inexpensive, rapid, and easy to perform and reliably guides BC early detection. Moreover, the association between elevated BC-DETECT values and disease severity may propose its potential role as prognostic marker.
© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.

Entities:  

Keywords:  BC-DETECT; Biomarker; Breast cancer; Diagnosis; HE4; TFF3

Mesh:

Substances:

Year:  2022        PMID: 34994942     DOI: 10.1007/s12282-021-01328-8

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   3.307


  28 in total

1.  Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium.

Authors:  R Poulsom; A M Hanby; E N Lalani; F Hauser; W Hoffmann; G W Stamp
Journal:  J Pathol       Date:  1997-09       Impact factor: 7.996

2.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

Authors:  C Kirchhoff; I Habben; R Ivell; N Krull
Journal:  Biol Reprod       Date:  1991-08       Impact factor: 4.285

3.  Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Authors:  Mary T Galgano; Garret M Hampton; Henry F Frierson
Journal:  Mod Pathol       Date:  2006-06       Impact factor: 7.842

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study.

Authors:  Umut Riza Gündüz; Meral Gunaldi; Nilgun Isiksacan; Seyda Gündüz; Yildiz Okuturlar; Hakan Kocoglu
Journal:  Mol Clin Oncol       Date:  2016-06-03

6.  Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?

Authors:  Abdelfattah M Attallah; Mohamed El-Far; Mohamed M Omran; Sanaa O Abdallah; Mohamed A El-Desouky; Ibrahim El-Dosoky; Mohamed A Abdelrazek; Ahmed A Attallah; Mohamed A Elweresh; Gamal E Abdel Hameed; Hadil A Shawki; Karim S Salama; Ahmed M El-Waseef
Journal:  Tumour Biol       Date:  2014-07-30

Review 7.  Emerging roles of long non-coding RNAs in breast cancer biology and management.

Authors:  I Amelio; F Bernassola; E Candi
Journal:  Semin Cancer Biol       Date:  2020-06-30       Impact factor: 15.707

8.  Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.

Authors:  Yuko Ishibashi; Hiroshi Ohtsu; Masako Ikemura; Yasuko Kikuchi; Takayoshi Niwa; Kotoe Nishioka; Yoshihiro Uchida; Hirona Miura; Susumu Aikou; Toshiaki Gunji; Nobuyuki Matsuhashi; Yasukazu Ohmoto; Takeshi Sasaki; Yasuyuki Seto; Toshihisa Ogawa; Keiichiro Tada; Sachiyo Nomura
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

9.  Expression of the pNR-2/pS2 protein in diverse human epithelial tumours.

Authors:  J A Henry; M K Bennett; N H Piggott; D L Levett; F E May; B R Westley
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

10.  HE4, A New Potential Tumor Marker for Early Diagnosis and Predicting of Breast Cancer Progression.

Authors:  Nazanin Mirmohseni Namini; Alireza Abdollahi; Monireh Movahedi; Amirnader Emami Razavi; Reza Saghiri
Journal:  Iran J Pathol       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.